Skip to content

Menu

Network by SubjectChannelsBlogsHomeAboutContact
AI Legal Journal logo
Subscribe
Search
Close
PublishersBlogsNetwork by SubjectChannels
Subscribe

Big News in AI Policy: Proposed 10-Year Moratorium on State AI Regulation

By Kimberly Chew & Kathleen Snyder on May 19, 2025
Email this postTweet this postLike this postShare this post on LinkedIn

Artificial intelligence (AI) continues to dominate headlines—not just for its technological leaps, but also for the policies shaping its future. In a major development, a new Republican-backed tax bill, released by the House Energy and Commerce Committee on May 11, 2025, seeks to preempt states from regulating AI models for the next decade. If passed, this bill would prevent state laws governing AI systems, allowing only limited exceptions for measures that simply facilitate or streamline AI development and deployment. Laws attempting to regulate artificial intelligence models, artificial intelligence systems, or automated decisions systems would be disallowed during the 10 year period.

This proposed federal approach aligns with the current administration’s emphasis on AI innovation over regulation, reflecting a belief that a unified, national policy will spur American competitiveness in this rapidly evolving field.

A Patchwork of State Activity

The push for a federal moratorium comes as states have been increasingly active in the AI policy arena. Nearly 700 AI-related bills were considered across the country last year, and 113 were enacted into law. Comprehensive state legislation passed in Colorado and Utah both have an impact on healthcare as does California’s Artificial Intelligence in Healthcare Services Bill AB3030, which requires that any AI-generated communications involving patient clinical information in California healthcare facilities include a disclaimer about the use of generative AI and instructions for contacting a human healthcare provider. As AI technologies become more powerful and pervasive, state lawmakers have been eager to step in—sometimes out of concern for consumer protection, sometimes to ensure ethical development, and sometimes simply to keep pace with technological change.

Would a 10-Year Prohibition Foster Innovation?

Supporters of the proposed moratorium argue that a decade-long prohibition on state-level AI regulation would create a stable environment for innovation. Here are some of the potential advantages:

  • Reduced Compliance Costs: Companies wouldn’t have to navigate 50 different regulatory regimes, lowering the barrier to entry for startups and reducing legal uncertainty.
  • Global Competitiveness: By prioritizing innovation, the U.S. could maintain its leadership in AI, especially as countries like China and the EU ramp up their own efforts.

However, there are also significant disadvantages to consider:

  • Stifling Local Solutions: States often serve as “laboratories of democracy,” experimenting with new approaches that can inform national policy. A moratorium could prevent states from responding to unique local needs or emerging risks.
  • Potential for Regulatory Gaps: With AI evolving rapidly, a 10-year freeze could leave critical issues—such as privacy, discrimination, and safety—unaddressed at the state level.
  • Public Trust: Without robust safeguards, the public may lose confidence in AI systems, potentially slowing adoption and innovation in the long run.

State-Level Innovation: A Testing Ground for AI Policy

Historically, states have played a vital role in protecting consumers and setting standards as new technologies emerge. From data privacy to environmental protection, state-level action has often paved the way for broader reforms. In the context of AI, states are well-positioned to:

  • Respond Quickly: State legislatures can often act faster than Congress, addressing new risks as they arise.
  • Tailor Solutions: States can craft policies that reflect local values and concerns, whether that’s disclosing AI’s use in healthcare or ensuring transparency in government use of AI.
  • Pilot New Approaches: By experimenting with different regulatory models, states can provide valuable insights into what works—and what doesn’t—before national standards are set.

That said, the rapid pace of AI development and its cross-border impacts do pose challenges for state-level regulation. There’s a real risk of fragmentation, with companies facing conflicting requirements that stifle growth and innovation.

What’s Next?

The debate over AI regulation is far from settled. As Congress considers this sweeping moratorium, policymakers will need to weigh the benefits of a unified national approach against the risks of stifling local innovation and oversight.

We are following AI developments closely, especially as they impact healthcare. If you have questions relating to potential federal preemption as to AI regulation or AI trends in healthcare or the life sciences, contact Kimberly Chew, Kathleen Snyder, or your Husch Blackwell attorney. 

Photo of Kimberly Chew Kimberly Chew

As a former life sciences researcher, Kimberly utilizes her ability to understand and explain complex topics to advise clients as to regulatory and legal liability issues. With a focus on litigation and discovery, she manages the discovery program for complex product liability and

…

As a former life sciences researcher, Kimberly utilizes her ability to understand and explain complex topics to advise clients as to regulatory and legal liability issues. With a focus on litigation and discovery, she manages the discovery program for complex product liability and toxic tort cases as national counsel.

Kimberly works with the firm’s innovative and award-winning Asbestos Litigation team in helping clients manage their risk profiles and in defending large national dockets. Businesses, academic and medical research centers, premises owners, contractors, and manufacturers are among those who rely on Kimberly’s broad range of litigation and regulatory experience. As national coordinating counsel, she coordinates the discovery for thousands of cases—drafting, responding to and preparing discovery and trial support documents for complex cases throughout the nation.

Kimberly has advised clients in matters of product liability, environmental matters, and legal matters regarding Schedule I controlled substances that involve laws such as the Controlled Substances Act, healthcare and research study regulations under the California Business & Professions Code, requirements relating to DEA licensing and registration of controlled substances, CERCLA/Superfund, RCRA, California Proposition 65, and other alleged solid and liquid hazardous waste violations in response to federal and state agency inspections.

Kimberly is the co-founder and co-lead of the firm’s Psychedelic and Emerging Therapies practice group. Kimberly’s background in biotech startups as a research scientist gives her a unique perspective in emerging areas of law such as psychedelic therapeutics. Psychedelics have garnered headline news as breakthrough medicines for the treatment of psychiatric conditions, including PTSD and major depression. Kimberly keeps current on the academic and commercial research and drug discovery efforts in this rapidly developing field so as to assist clients in navigating and complying with complex regulatory issues and protecting and commercializing intellectual property.

Knowledgeable and energetic, Kimberly is known for identifying key strategies in challenging cases, then easily communicating those ideas to clients and legal teams in order to move forward with the best solutions.

Prior to her admission into the state bar, Kimberly externed with the California Attorney General’s Office.

Read more about Kimberly ChewKimberly's Linkedin Profile
Show more Show less
Kathleen Snyder

Kathleen is a strategic partner to clients. She provides holistic practical advice at the intersection of healthcare and technology. With a broad background in healthcare, digital health, AI, and tech transfer, Kathleen supports healthcare and life sciences clients’ IP licensing, commercial contracting, and

…

Kathleen is a strategic partner to clients. She provides holistic practical advice at the intersection of healthcare and technology. With a broad background in healthcare, digital health, AI, and tech transfer, Kathleen supports healthcare and life sciences clients’ IP licensing, commercial contracting, and regulatory needs.

With 20 years of experience in the healthcare field, Kathleen has an intrinsic understanding of the healthcare landscape, particularly as it applies to health information exchange and healthcare delivery, including managed care and value-based contracting. Her technology-focused transactional practice, coupled with her regulatory experience, gives her a unique perspective that allows her to provide holistic advice to clients.

Read more about Kathleen Snyder
Show more Show less
  • Posted in:
    Health Care
  • Blog:
    Healthcare Law Insights
  • Organization:
    Husch Blackwell LLP
  • Article: View Original Source

LexBlog logo
Copyright © 2025, LexBlog. All Rights Reserved.
Legal content Portal by LexBlog LexBlog Logo